Journal article
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study
Abstract
OBJECTIVE: BAY 12-9566 (tanomastat) is a biphenyl matrix metalloprotease inhibitor (MMPI) with antiangiogenic and antimetastatic properties in vivo. The objective of the study was to determine whether the addition of BAY 12-9566 after optimal response to chemotherapy could improve time to progression (TTP).
PATIENTS AND METHODS: Patients enrolled in the study had received 6-9 cycles of platinum/paclitaxel containing chemotherapy for stage III …
Authors
Hirte H; Vergote IB; Jeffrey JR; Grimshaw RN; Coppieters S; Schwartz B; Tu D; Sadura A; Brundage M; Seymour L
Journal
Gynecologic Oncology, Vol. 102, No. 2, pp. 300–308
Publisher
Elsevier
Publication Date
August 2006
DOI
10.1016/j.ygyno.2005.12.020
ISSN
0090-8258
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiphenyl CompoundsCombined Modality TherapyDisease-Free SurvivalDouble-Blind MethodFemaleHumansMatrix Metalloproteinase InhibitorsMiddle AgedOrganic ChemicalsOrganoplatinum CompoundsOvarian NeoplasmsPaclitaxelPhenylbutyratesPlacebosProtease InhibitorsQuality of Life